Global Cancer Monoclonal Antibodies Market – Industry Trends and Forecast to 2029

Global Cancer Monoclonal Antibodies Market, By Application (Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Acute Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Solid Tumor, Epithelial Tumor, Others), Route of Administration (Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029

Cancer Monoclonal Antibodies Market Analysis and Size

The global cancer monoclonal antibodies market is expected to witness significant growth during the forecast period. Growing cases of cancer & other type of solid tumor drives the cancer monoclonal antibodies market. The factors responsible for the market growth are increased family history with immune disease; adaptation of unhealthy lifestyle also boosts up the cancer monoclonal antibodies market growth. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global cancer monoclonal antibodies market in the forecast period 2022-2029. The expected CAGR of global cancer monoclonal antibodies market  is tend to be around 14% in the mentioned forecast period. The market was valued at USD 36 billion in 2021, and it would grow upto USD 102.69 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Monoclonal antibody (mAb) therapy is a type of immunotherapy in which monoclonal antibodies attach to specific proteins or cells due to their monovalent affinity, these antibodies can bind to a specific antigen when administered because of their site specificity, monoclonal antibodies are an important tool for detecting or purifying substances; thus, they have important applications in biochemistry, molecular biology, and medicine. It is critical to the healthcare sector and is thus expected to rise significantly during the forecast period.

Report Scope and Market Segmentation

Global Cancer Monoclonal Antibodies Market Dynamics

Drivers

• Increase in Cancer Cases

The rise in cancer cases globally boosts the global small cell lung cancer (SCLC) therapeutics market in the forecast period As per the reports of the American Cancer Society Statistics in 2016, majority of cases of SCLC mostly occur in individuals between the age group of 60-80 years with an estimated global death rate being 30,000 per year. In addition to this, as per the reports of WHO, lung cancer is the second most dominant cancer in men and women causing 1.59 million deaths in 2012. This boost the market growth.

• Development of Diversified Treatments

Treatments such as phage or yeast display, and transgenic mice, for human monoclonal antibodies generation and also employment of advanced genetic engineering technology offer great benefits to the patients. Thus, it boosts the market growth.

Opportunities

• Patent Expiration Encourages New Launches

The patent expiration of old companies can create better opportunities for the new market players. Adopting combination therapies is a significant factor contributing to the growth of the monoclonal antibodies market. Further, R&D fundings are an add-on to the market.

• Rising Healthcare Awareness

Awareness among patients as well as healthcare providers about the incidence of small cell lung cancer (SCLC) is on the rise. Patients and doctors are now more actively participating in learning about the therapies available for treating these severe diseases. This is one of the most important drivers in the market. This creates more opportunity in the market.

Restraints/Challenges

• Lack of Skilled Professionals

Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global cancer monoclonal antibodies market over a forecast period.

• Increasing Cost Of Treatments

The huge expenditure required for the treatment methods surely hamper the market growth. Many of the treatments involved in this disease require high cost and thus at times gets difficult for many people, especially the ones in the rural areas. Thus, this can act as a major hindrance factor for the market.

This global cancer monoclonal antibodies market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global cancer monoclonal antibodies market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Cancer Monoclonal Antibodies Market Scope

The global cancer monoclonal antibodies market is segmented on the basis of application, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Application

• Non-Hodgkin Lymphoma
• Hodgkin Lymphoma
• Acute Myelogenous Leukemia
• Chronic Lymphocytic Leukemia
• Solid Tumor
• Epithelial Tumor
• Others

Route of Administration

• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Cancer Monoclonal Antibodies Market Regional Analysis/Insights

The global cancer monoclonal antibodies market is analysed and market size insights and trends are provided by application, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global cancer monoclonal antibodies market  report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific is expected to have the highest market growth due to increased prevalence of cancer and related disorders and number of generic drugs.

North America dominates the market due to focus of global market players and novel technologies.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Cancer Monoclonal Antibodies Market Share Analysis

The global cancer monoclonal antibodies market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global cancer monoclonal antibodies market.

Key players operating in the global cancer monoclonal antibodies market include:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Lilly (U.S.)
• Merck & Co., Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Fresenius Kabi AG (Germany)
• Akorn Incorporated (U.S.)
• Teva Pharmaceutical Industries Ltd (Israel)